AnaptysBio has delivered four consecutive earnings beats with an average positive surprise exceeding 59%, momentum is technically constructive with a golden cross and above all moving averages, but the pipeline is concentrated in a single asset partnered with one counterparty, and quality remains below the minimum threshold.
Thesis pillars
- Pipeline Counterparty Concentration Risk↓Deteriorating
- Quality Below Minimum Threshold↑Improving
- Exceptional Earnings Beat Pattern→Stable
- +1 more pillar — see the Why tab for full reasoning
AnaptysBio, Inc. (ANAB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $51.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.26; Negative price momentum.
AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned clinical-stage candidates: rosnilimab (Phase 2b completed for RA), ANB033 (Phase 1b for celiac disease and EoE), and ANB101 (Phase 1a). Revenue came from GSK milestones and... Read more
Sell if holding. Engine safety override at $51.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.26; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news boost analyst 0.70, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About AnaptysBio, Inc.
About AnaptysBio, Inc.
AnaptysBio's lead asset, rosnilimab, completed a 424-patient global Phase 2b trial for moderate-to-severe rheumatoid arthritis in 2025, meeting its primary DAS28-CRP endpoint across all three doses; ACR20 response at the 600 mg Q2W dose reached 75.2% versus 52.8% for placebo. The company had no product revenue in 2025, earning milestone and royalty income from GSK's Jemperli collaboration — GSK reported $1.1 billion in Jemperli sales for 2025, up more than 80% from $598 million in 2024.
AnaptysBio earns revenue from two financial collaborations: tiered royalties from GSK on Jemperli net sales (ranging from 8% below $1.0 billion to 25% above $2.5 billion under Amendment No. 3 to the GSK Agreement), with a $250.0 million royalty monetization agreement with Sagard Healthcare Royalty Partners limiting near-term cash receipts; and a license to Vanda Pharmaceuticals for imsidolimab (IL-36R antagonist), which provided a $10.0 million upfront payment plus $5.0 million for drug supply and up to $35.0 million in future milestones plus 10% royalties on net sales. In April 2026, the company completed the spin-off of First Tracks Biotherapeutics to hold those two financial collaborations. Two additional wholly owned programs are in early development: ANB033 (CD122 antagonist) is in Phase 1b cohorts for celiac disease and eosinophilic esophagitis, and ANB101 (BDCA2 modulator) entered a Phase 1 trial in healthy volunteers in March 2025.
Show full overview
The critical near-term milestone for AnaptysBio is the Phase 3 advancement decision for rosnilimab in rheumatoid arthritis, which the company stated it plans to update on in the first half of 2026. The 10-K discloses that while rosnilimab achieved positive Phase 2b results in RA, a prior Phase 2 trial in ulcerative colitis was not positive — demonstrating the indication-level binary risk for a multi-indication development program. The FDA accepted Vanda's BLA for imsidolimab in February 2026 with a target action date of December 12, 2026; approval would trigger the $5.0 million FDA milestone under the Vanda License Agreement, now accruing to First Tracks Biotherapeutics following the spin-off.
See also: Healthcare · Biotechnology
From AnaptysBio, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-09-26Recent Developments — AnaptysBio, Inc.
Latest news
- NEWS ANAB Rated Outperform by Leerink Partners -- Price Target Raised to $85 - GuruFocus — GuruFocus positive
- NEWS AnaptysBio (NASDAQ:ANAB) Hits New 1-Year High - Time to Buy? - MarketBeat — MarketBeat positive
- NEWS AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release - MSN — MSN negative
- NEWS Why Is AnaptysBio Stock Soaring Monday? - AnaptysBio (NASDAQ:ANAB) - Benzinga — Benzinga positive
- NEWS AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Yahoo Finance — Yahoo Finance positive
Generated 2026-09-26T02:41:57Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyGSK10-K Item 1A: 'Our existing collaboration with GSK and other collaborations are important to our business ... If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.'
- HIGHpipelinerosnilimab10-K Item 1A: 'We are assessing advancement to Phase 3 of clinical development of rosnilimab for RA, and have no history of commercializing biotechnology products'
Material Events(8-K, last 90d)
- 2026-05-11Item 5.02LOWChristopher M. Murphy appointed CFO of AnaptysBio effective May 11, 2026; previously CFO of Third Harmonic Bio (Jan 2024–Dec 2025). Clean handoff; no disagreement with company practices cited.SEC filing →
- 2026-04-20Item 1.01MEDIUMAnaptysBio entered Separation and Distribution Agreement and Transition Services Agreement on April 20, 2026 completing spin-off of First Tracks Biotherapeutics; TRAX shares distributed pro rata to ANAB shareholders; TRAX began trading on Nasdaq.SEC filing →
- 2026-03-27Item 1.01MEDIUMBoard approved spin-off of First Tracks Biotherapeutics on March 26, 2026; SpinCo entered private placement Purchase Agreement at $13.81/share for approximately $80 million gross proceeds from third-party investors.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $51.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.26; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $47.97. Score 6.3/10, moderate confidence.
Take-profit target: $77.00 (+51.0% upside). Prior stop was $47.97. Stop-loss: $47.97.
Concentration risk — Counterparty: GSK; Concentration risk — Pipeline: rosnilimab; Risk below floor (1.7 < 3.0).
AnaptysBio, Inc. trades at a P/E of N/A (forward 9.3). TrendMatrix value score: 5.7/10. Verdict: Sell.
17 analysts cover ANAB with a consensus score of 4.3/5. Average price target: $89.
What does AnaptysBio, Inc. do?AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned...
AnaptysBio develops antibody therapeutics for autoimmune and inflammatory diseases with three wholly owned clinical-stage candidates: rosnilimab (Phase 2b completed for RA), ANB033 (Phase 1b for celiac disease and EoE), and ANB101 (Phase 1a). Revenue came from GSK milestones and royalties on Jemperli and Vanda licensing fees; in April 2026 those financial collaborations were spun off into First Tracks Biotherapeutics.